GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » EPS (Diluted)

CNBX Pharmaceuticals (CNBX Pharmaceuticals) EPS (Diluted) : $-0.06 (TTM As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals EPS (Diluted)?

CNBX Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Feb. 2024 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.06.

CNBX Pharmaceuticals's EPS (Basic) for the three months ended in Feb. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.06.

CNBX Pharmaceuticals's EPS without NRI for the three months ended in Feb. 2024 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was 79.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, CNBX Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 79.00% per year. The lowest was -100.20% per year. And the median was 12.10% per year.


CNBX Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for CNBX Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals EPS (Diluted) Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 -12.00 -2.40 -3.59 -0.42

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.33 -0.02 -0.03 - -0.01

Competitive Comparison of CNBX Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, CNBX Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's PE Ratio falls into.



CNBX Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

CNBX Pharmaceuticals's Diluted EPS for the fiscal year that ended in Aug. 2023 is calculated as

Diluted EPS (A: Aug. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.71-0)/8.825
=-0.42

CNBX Pharmaceuticals's Diluted EPS for the quarter that ended in Feb. 2024 is calculated as

Diluted EPS (Q: Feb. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.325-0)/30.988
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CNBX Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary